Last Price$29.80.3%
Market Cap$13.0B
P/OCF LTM
9.7x
5Y avg
8.8x
Medical - Devices industry
median
(0.3x)
Stock quality & Intrinsic value
6/10
1.3% undervalued
Smith & Nephew plc P/OCF LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/OCF LTM | 17.3x | 15.9x | 15.0x | 6.9x | 8.3x | 6.4x | 5.3x | 5.7x | 7.3x | 10.0x | 10.0x | 7.0x | 7.6x | 8.3x | 10.0x | 9.9x | 7.5x | 6.1x | 10.9x | 9.7x |
Overvalued or undervalued?
Check the intrinsic value for SNN
and see if it's the right time to invest.
Smith & Nephew plc (SNN) P/OCF LTM comparison analysis
General
LTM P/OCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Smith & Nephew plcSNN
8.1x
4.7%
(21.7%)
7.1%
Median Peer Set
27.6x
4.2%
59.2%
12.5%
Edwards Lifesciences CorporationEW
74.6x
(9.4%)
202.2%
76.7%
Boston Scientific CorporationBSX
40.9x
17.6%
16.7%
11.1%
Insulet CorporationPODD
40.0x
22.1%
101.7%
20.2%
Stryker CorporationSYK
32.8x
10.2%
(5.8%)
13.2%
DexCom, Inc.DXCM
28.3x
11.3%
(1.4%)
14.3%
Abbott LaboratoriesABT
27.0x
4.6%
134.5%
31.9%
STERIS plcSTE
19.8x
3.6%
257.9%
7.4%
Medtronic plcMDT
16.4x
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
14.5x
3.8%
(9.4%)
11.8%
Koninklijke Philips N.V.PHG
13.7x
(0.8%)
122.5%
(3.9%)
SNN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 2,552.0 6.6% | 2,779.0 8.9% | 3,369.0 21.2% | 3,801.0 12.8% | 3,772.0 (0.8%) | 3,962.0 5.0% | 4,270.0 7.8% | 4,137.0 (3.1%) | 4,351.0 5.2% | 4,617.0 6.1% | 4,634.0 0.4% | 4,669.0 0.8% | 4,765.0 2.1% | 4,904.0 2.9% | 5,138.0 4.8% | 4,560.0 (11.2%) | 5,212.0 14.3% | 5,215.0 0.1% | 5,549.0 6.4% | 5,810.0 4.7% |
| Cost of Goods Sold (COGS) | 701.0 | 769.0 | 994.0 | 1,077.0 | 1,030.0 | 1,031.0 | 1,140.0 | 1,070.0 | 1,100.0 | 1,162.0 | 1,143.0 | 1,272.0 | 1,248.0 | 1,298.0 | 1,338.0 | 1,396.0 | 1,543.0 | 1,540.0 | 1,730.0 | 1,764.0 |
% margin | 1,851.0 72.5% | 2,010.0 72.3% | 2,375.0 70.5% | 2,724.0 71.7% | 2,742.0 72.7% | 2,931.0 74.0% | 3,130.0 73.3% | 3,067.0 74.1% | 3,251.0 74.7% | 3,455.0 74.8% | 3,491.0 75.3% | 3,397.0 72.8% | 3,517.0 73.8% | 3,606.0 73.5% | 3,800.0 74.0% | 3,164.0 69.4% | 3,669.0 70.4% | 3,675.0 70.5% | 3,819.0 68.8% | 4,046.0 69.6% |
| Operating Expenses | 1,345.0 | 1,453.0 | 1,766.0 | 2,080.0 | 2,019.0 | 2,011.0 | 2,268.0 | 2,221.0 | 2,441.0 | 2,706.0 | 2,863.0 | 2,596.0 | 2,583.0 | 2,743.0 | 2,985.0 | 2,869.0 | 3,076.0 | 3,225.0 | 3,394.0 | 3,389.0 |
| Research & Development Expenses (R&D) | 122.0 | 120.0 | 142.0 | 152.0 | 155.0 | 151.0 | 167.0 | 171.0 | 231.0 | 235.0 | 222.0 | 230.0 | 223.0 | 246.0 | 292.0 | 307.0 | 356.0 | 345.0 | 299.0 | 289.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,212.0 | 1,319.0 | 1,530.0 | 1,796.0 | 1,864.0 | 1,860.0 | 2,101.0 | 2,050.0 | 2,210.0 | 2,471.0 | 2,641.0 | 2,366.0 | 2,360.0 | 2,497.0 | 2,693.0 | 2,562.0 | 2,720.0 | 2,880.0 | 2,890.0 | 3,100.0 |
% margin | 422.0 16.5% | 537.0 19.3% | 493.0 14.6% | 630.0 16.6% | 723.0 19.2% | 920.0 23.2% | 862.0 20.2% | 846.0 20.4% | 810.0 18.6% | 749.0 16.2% | 628.0 13.6% | 801.0 17.2% | 934.0 19.6% | 863.0 17.6% | 815.0 15.9% | 295.0 6.5% | 593.0 11.4% | 315.0 6.0% | 425.0 7.7% | 657.0 11.3% |
| Interest Income | 27.0 | 19.0 | 10.0 | 5.0 | 2.0 | 3.0 | 4.0 | 11.0 | 14.0 | 13.0 | 11.0 | 6.0 | 6.0 | 8.0 | 10.0 | 6.0 | 6.0 | 14.0 | 34.0 | 0.0 |
| Interest Expense | 18.0 | 9.0 | 40.0 | 71.0 | 42.0 | 18.0 | 12.0 | 9.0 | 10.0 | 35.0 | 49.0 | 52.0 | 57.0 | 59.0 | 65.0 | 62.0 | 80.0 | 80.0 | 139.0 | 0.0 |
| Pre-tax Income | 428.0 | 550.0 | 469.0 | 564.0 | 670.0 | 895.0 | 848.0 | 1,100.0 | 802.0 | 714.0 | 559.0 | 1,062.0 | 879.0 | 781.0 | 743.0 | 246.0 | 586.0 | 235.0 | 290.0 | 498.0 |
% effective tax rate | 126.0 29.4% | 156.0 28.4% | 153.0 32.6% | 187.0 33.2% | 198.0 29.6% | 280.0 31.3% | 266.0 31.4% | 371.0 33.7% | 246.0 30.7% | 213.0 29.8% | 149.0 26.7% | 278.0 26.2% | 112.0 12.7% | 118.0 15.1% | 143.0 19.2% | (202.0) (82.1%) | 62.0 10.6% | 12.0 5.1% | 27.0 9.3% | 86.0 17.3% |
% margin | 333.0 13.0% | 745.0 26.8% | 316.0 9.4% | 377.0 9.9% | 472.0 12.5% | 615.0 15.5% | 582.0 13.6% | 729.0 17.6% | 556.0 12.8% | 501.0 10.9% | 410.0 8.8% | 784.0 16.8% | 767.0 16.1% | 663.0 13.5% | 600.0 11.7% | 448.0 9.8% | 524.0 10.1% | 223.0 4.3% | 263.0 4.7% | 412.0 7.1% |
| EPS | 0.36 | 0.79 | 0.34 | 0.43 | 0.53 | 0.69 | 0.65 | 0.81 | 0.62 | 0.56 | 0.46 | 0.88 | 0.88 | 0.76 | 0.69 | 0.51 | 0.60 | 0.25 | 0.60 | 0.47 |
| Diluted EPS | 0.35 | 0.79 | 0.34 | 0.42 | 0.53 | 0.69 | 0.65 | 0.81 | 0.61 | 0.56 | 0.46 | 0.88 | 0.88 | 0.76 | 0.68 | 0.51 | 0.60 | 0.25 | 0.60 | 0.47 |
% margin | 683.0 26.8% | 703.0 25.3% | 721.0 21.4% | 910.0 23.9% | 1,039.0 27.5% | 1,211.0 30.6% | 1,164.0 27.3% | 1,182.0 28.6% | 1,184.0 27.2% | 1,186.0 25.7% | 1,115.0 24.1% | 1,266.0 27.1% | 1,393.0 29.2% | 1,287.0 26.2% | 1,320.0 25.7% | 866.0 19.0% | 1,242.0 23.8% | 943.0 18.1% | 979.0 17.6% | 1,237.0 21.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Smith & Nephew plc's P/OCF LTM?
As of today, Microsoft Corp's last 12-month P/OCF LTM is 9.7x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/OCF LTM for Smith & Nephew plc have been 8.7x over the past three years, and 9.2x over the past five years.
2) Is Smith & Nephew plc's P/OCF LTM Good?
As of today, Smith & Nephew plc's P/OCF LTM is 9.7x, which is higher than industry median of (0.3x). It indicates that Smith & Nephew plc's P/OCF LTM is Bad.